Technology | EP Mapping and Imaging Systems | April 26, 2019

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

Company also announces CE Mark approval in Europe for AcQMap contact mapping software

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

April 26, 2019 — Acutus Medical announced U.S. Food and Drug Administration (FDA) clearance of its second-generation AcQMap platform, along with CE Mark approval for its AcQMap contact mapping software.

AcQMap offers expanded functionality that provides physicians with more options to inform individualized patient therapy. All AcQMap systems retain the ability to quickly reconstruct atrial anatomy using ultrasound and map electrical patterns using non-contact, charge density technology, creating ultra-high-resolution 3-D images in real time.

"The contact mapping speed with the new Acutus system was extremely fast, which made it very easy to use," said Christian Meyer, M.D., University Medical Center Hamburg-Eppendorf, Hamburg, Germany. "Clinically, having this capability available on one system that also does non-contact mapping allows me to do exactly what makes sense case by case. For routine cases, my treatment strategy can be confirmed using conventional mapping catheters. In more complex cases, such as atrial fibrillation, I can gather more comprehensive data about each patient's anatomy and arrhythmia in real time with the non-contact charge density catheter, making AcQMap the complete atrial mapping solution."

Cardiac ablation treatment can improve quality of life for patients with atrial arrhythmias such as atrial fibrillation (AF). AF affects more than 33 million people globally, and increases the risk of stroke and heart failure.1,2 AcQMap enables physicians to uncover the electrical activation pattern of the heart with real-time visualization during electrophysiology procedures. With non-contact mapping, physicians see full-chamber, continuous beat-by-beat arrhythmia conduction and can locate arrhythmias outside the pulmonary veins to inform their treatment strategy, enabling an iterative map-ablate-remap approach.

Acutus Medical's contact mapping software is compatible with both first- and second-generation AcQMap platforms and will be installed on all European systems in Q3 2019. The second-generation AcQMap system is built to support future software innovations and will be available in the U.S. in Q3 2019.

For more information: www.acutusmedical.com

References

1. Staerk L, Sherer JA, Ko D, et al. Atrial Fibrillation. Circ Res 2017;120:1501-17. DOI: 10.1161/CIRCRESAHA.117.309732.

2. Chugh, S.S., Havmoeller, R., Narayanan, K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circ Feb 25. 2014; 129: 837–847. DOI: 10.1161/CIRCULATIONAHA.113.005119.


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now